Literature DB >> 11564081

Intracellular Fas ligand is elevated in T lymphocytes in severe aplastic anaemia.

A Luther-Wyrsch1, C Nissen, A Wodnar-Filipowicz.   

Abstract

Increased expression of Fas receptor by haemopoietic progenitors in aplastic anaemia (AA) suggests that excessive apoptosis contributes to multilineage bone marrow (BM) failure. To investigate the role of Fas ligand (FasL) in triggering progenitor cell death, we examined FasL levels in T lymphocytes of patients with severe untreated AA (n = 8). Expression of FasL on the surface of CD3+ cells was not detectable. However, flow cytometric analysis of saponin-permeabilized cells demonstrated higher levels of intracellular FasL in AA than in normal T cells (P < 0.005), both prior to and following activation with phytohaemagglutinin. Confocal microscopy revealed that FasL-specific signals overlapped with cathepsin D staining, indicating that intracellular FasL is stored in lysosomal granules. Levels of intracellular FasL in patients examined 1 month after immunosuppression with antilymphocyte globulin and cyclosporin A were lower than prior to treatment. The caspase inhibitors, DEVD and zVAD, enhanced colony formation and prolonged survival of AA BM cells in liquid cultures by about 10-fold (P < 0.05). Taken together, these data provide further evidence that apoptosis by the Fas/FasL system plays a role in the depletion of stem cells in AA.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11564081     DOI: 10.1046/j.1365-2141.2001.03026.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  6 in total

1.  Interferon-gamma-induced gene expression in CD34 cells: identification of pathologic cytokine-specific signature profiles.

Authors:  Weihua Zeng; Akira Miyazato; Guibin Chen; Sachiko Kajigaya; Neal S Young; Jaroslaw P Maciejewski
Journal:  Blood       Date:  2005-08-30       Impact factor: 22.113

2.  Treg sensitivity to FasL and relative IL-2 deprivation drive idiopathic aplastic anemia immune dysfunction.

Authors:  Shok Ping Lim; Benedetta Costantini; Syed A Mian; Pilar Perez Abellan; Shreyans Gandhi; Marc Martinez Llordella; Juan Jose Lozano; Rita Antunes Dos Reis; Giovanni A M Povoleri; Thanos P Mourikis; Ander Abarrategi; Linda Ariza-McNaughton; Susanne Heck; Jonathan M Irish; Giovanna Lombardi; Judith C W Marsh; Dominique Bonnet; Shahram Kordasti; Ghulam J Mufti
Journal:  Blood       Date:  2020-08-13       Impact factor: 22.113

3.  Lymphocytes with aberrant expression of Fas or Fas ligand attenuate immune bone marrow failure in a mouse model.

Authors:  Stephanie O Omokaro; Marie J Desierto; Michael A Eckhaus; Felicia M Ellison; Jichun Chen; Neal S Young
Journal:  J Immunol       Date:  2009-03-15       Impact factor: 5.422

Review 4.  Mesenchymal stem cells in immune-mediated bone marrow failure syndromes.

Authors:  Maria-Christina Kastrinaki; Konstantia Pavlaki; Aristea K Batsali; Elisavet Kouvidi; Irene Mavroudi; Charalampos Pontikoglou; Helen A Papadaki
Journal:  Clin Dev Immunol       Date:  2013-12-10

Review 5.  Genetic associations in acquired immune-mediated bone marrow failure syndromes: insights in aplastic anemia and chronic idiopathic neutropenia.

Authors:  Irene Mavroudi; Helen A Papadaki
Journal:  Clin Dev Immunol       Date:  2012-08-26

Review 6.  Hematopoietic Stem Cell Regulation by Type I and II Interferons in the Pathogenesis of Acquired Aplastic Anemia.

Authors:  Julianne N P Smith; Vikramjit S Kanwar; Katherine C MacNamara
Journal:  Front Immunol       Date:  2016-08-29       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.